目的 评价头孢卡品酯对我国近三年临床分离致病菌所致小鼠败血症的体内抗菌作用.方法 以0.5mL最小致死量(MLD)腹腔注射细菌感染小鼠,建立小鼠败血症实验模型,灌胃0.5mL不同剂量的抗菌药物,记录给药后1～7d内小鼠成活率,用BLISS法计算50％、95％有效剂量(ED50、ED95)及P值.结果 对4株临床分离致病菌进行了体内保护试验.结果显示,头孢卡品酯对不产ESBLs的大肠埃希菌、肺炎克雷伯菌以及甲氧西林敏感金葡菌、青霉素敏感肺炎链球菌的ED50值在0.381～3.613mg/kg,ED95值在1.304-17.939mg/kg.结论 头孢卡品酯对所测革兰阴性菌的体内抗菌作用优于革兰阳性菌.对体外抗菌活性优于头孢泊肟的菌株,体内抗菌作用也基本优于头孢泊肟酯.%Objective Evaluate the in vivo activity of Cefcapene proxetil in the experimental therapy of mouse septicemia caused by clinical isolated pathogenic bacteria in recent years in China. Methods The mice were intraperitoneally injected with 0.5mL minimum lethal dose (MLD) bacteria and experimental model of mouse septicemia was established. Cefcapene proxetil and Cefpodoxime proxetil were each oral administered in a single dose. The survival of the infected mice were monitored for 7 days, and the 50%, 95% effective dose (ED50 and ED95) was determined by the BLISS method. Results The ED50 and ED95 of Cefcapene proxetil against extended-spectrum beta-lactamase (ESBL) negative Escherichia coli, ESBL negative Klebsiella peumoniae, methicillin susceptibility Staphylococcus aureus (MSSA) and penicillin susceptibility Streptococcus pneumoniae were 0.267-8.081 mg/kg and 2.308-25.452 mg/kg, which were almost the same as that of cefpodoxime proxetil. CONCLUSLON: Cefcapene proxetil showed a good in vivo activity for gram-positive and negative bacterial.
展开▼
